Antithrombin Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Antithrombin Market is segmented by Usage (Therapeutics, Diagnosis, Research, and Others), Source, Type, Route, and Geography

Market Snapshot

antithrombin-market_Market Summary
Study Period: 2018 - 2026
Base Year: 2020
Fastest Growing Market: North America
Largest Market: Asia Pacific
CAGR: 4.1 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The growing incidence of conditions (like sepsis, congenital antithrombin deficiency, disseminated intravascular coagulation (DIC), extracorporeal membrane oxygenation (ECMO)), and elevated open-heart surgeries are likely to increase the growth of the global antithrombin market. Thrombotic diseases require a long term treatment of antithrombin drugs; this contributes to the increase in production and sales of Antithrombin. The increased usage of rapid diagnostic tests, which in turn use antithrombin, boosts the demand of the protein in the diagnostic field. The increased use of biologics and the high cost of antithrombin are the two factors constraining the growth of the market.

Scope of the Report

As per the scope of the report, antithrombin is a protein produced by the liver that inactivates thrombin and decreases the blood clotting.

By Usage
Therapeutics
Diagnostics
Research
Other
By Source
Human
Recombinant Goat milk
Others
By Type
Anticoagulant
Antiplatelet
Thrombolytic Drugs
By Route
Oral
Parenteral
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Therapeutics Segment is Expected to hold a Large Market Share Over the Forecast Period

Antithrombin can be used as therapeutics in conditions like cardiac surgeries, and in genetic condition like Antithrombin Deficiency. As per the data published by the American Society of Hematology 900,000 people in the United States develop blood clots yearly, and they are accountable for approximately 100,000 casualties each year. 

Furthermore, according to the National Organisation for Rare Disorders, every one person in 3000 to 5000 people in the United States has Type I antithrombin deficiency. The increasing prevalence of blood clotting diseases increases the therapeutics and diagnostic usage of Antithrombin.

Antithrombin Market

Asia-pacific region is Expected to be the Fastest Growing Region Over the Forecast Period

The Asia-pacific region is expected to show a high growth due to the developing nations such as India and China that are embracing new treatment procedures and techniques to combat various diseases. The increase in non-refundable incomes developing countries and their increasing capability to invest more money for advanced healthcare creates more opportunities for the market in the Asia Pacific. Although the occurrence of venous thromboembolism (VTE) in Asian populations is lesser than in Western countries, the total burden of VTE in Asia has been substantially underestimated. Factors that may explain the lower prevalence of VTE in Asian populations relative to Western populations comprise the incomplete availability of epidemiological data in Asia, ethnic differences in the genetic predilection to VTE, underdiagnoses, low awareness toward thrombotic disease, and possibly less symptomatic VTE in Asian patients. In recent years the awareness of the disease is increasing, raising the need for diagnosis and treatment.

Antithrombin Market 2

Competitive Landscape

The antithrombin market is moderately competitive and consists of several major players. Some of the major market players are CSL Limited, Grifols SA, Takeda Pharmaceuticals, Octapharma AG, LFB USA, Axis-Shield Plc, Siemens AG, Thermo Fisher Scientific, and Lee Biosolutions Inc.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing coagulation diseases and open heart surgeries

      2. 4.2.2 Increasing usage of diagnostic kits using Antithrombin

    3. 4.3 Market Restraints

      1. 4.3.1 Alternative supplements

      2. 4.3.2 High Cost of Antithrombin therapy

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Usage

      1. 5.1.1 Therapeutics

      2. 5.1.2 Diagnostics

      3. 5.1.3 Research

      4. 5.1.4 Other

    2. 5.2 By Source

      1. 5.2.1 Human

      2. 5.2.2 Recombinant Goat milk

      3. 5.2.3 Others

    3. 5.3 By Type

      1. 5.3.1 Anticoagulant

      2. 5.3.2 Antiplatelet

      3. 5.3.3 Thrombolytic Drugs

    4. 5.4 By Route

      1. 5.4.1 Oral

      2. 5.4.2 Parenteral

    5. 5.5 Geography

      1. 5.5.1 North America

        1. 5.5.1.1 United States

        2. 5.5.1.2 Canada

        3. 5.5.1.3 Mexico

      2. 5.5.2 Europe

        1. 5.5.2.1 Germany

        2. 5.5.2.2 United Kingdom

        3. 5.5.2.3 France

        4. 5.5.2.4 Italy

        5. 5.5.2.5 Spain

        6. 5.5.2.6 Rest of Europe

      3. 5.5.3 Asia-Pacific

        1. 5.5.3.1 China

        2. 5.5.3.2 Japan

        3. 5.5.3.3 India

        4. 5.5.3.4 Australia

        5. 5.5.3.5 South Korea

        6. 5.5.3.6 Rest of Asia-Pacific

      4. 5.5.4 Middle-East and Africa

        1. 5.5.4.1 GCC

        2. 5.5.4.2 South Africa

        3. 5.5.4.3 Rest of Middle-East and Africa

      5. 5.5.5 South America

        1. 5.5.5.1 Brazil

        2. 5.5.5.2 Argentina

        3. 5.5.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 CSL Limited

      2. 6.1.2 Grifols S.A

      3. 6.1.3 Takeda Pharmaceutical Company Limited

      4. 6.1.4 Octapharma AG

      5. 6.1.5 LFB USA

      6. 6.1.6 Axis-Shield Plc

      7. 6.1.7 Siemens AG

      8. 6.1.8 Thermo Fisher Scientific

      9. 6.1.9 Lee Biosolutions Inc.

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Antithrombin Market market is studied from 2018 - 2026.

The Antithrombin Market is growing at a CAGR of 4.1% over the next 5 years.

North America is growing at the highest CAGR over 2021- 2026.

Asia Pacific holds highest share in 2020.

Grifols, S.A., Octapharma AG, LFB USA, CSL Limited, Takeda Pharmaceutical Company Limited are the major companies operating in Antithrombin Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!